title: Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality.
abstract: BACKGROUND
  Advanced glycation end products (AGEs) accumulate in patients with end-stage renal disease (ESRD). The aim of this study was to investigate the potential influence of different modalities of renal replacement therapies on plasma AGE levels.
  
  
  METHODS
  The removal of AGEs by high-flux haemodialysis (HD) using standard and ultrapure dialysis fluid (SDF and UDF), by haemodiafiltration (HDF) and by haemofiltration (HF) was studied by fluorescence spectroscopy and by a carboxymethyllysine (CML)-specific ELISA. In addition, molecular weight distribution of fluorescent AGE products in serum of several patients was analysed by gel filtration.
  
  
  RESULTS
  The highest AGE-typical fluorescence was found in the serum of patients on HD using SDF (114,667+/-18,967 arbitrary units (AU)), followed by patients on HDF (86,912+/-24,411 AU, P<0.005), by patients on HD using UDF (74,953+/-21,152 AU, P<0.0001) and by patients on HF (74 039+/-17 027 AU, P<0.0001). Similar results were found for serum CML levels with the highest values in HD patients on SDF (1609+/-504 ng/ml), followed by patients on HF (1354+/-614 ng/ml, P<0.001), then by HD patients on UDF (1310+/-403 ng/ml, P<0.001) and by patients on HDF (1132+/-338 ng/ml, P<0.001). The removal rate of AGEs, as evaluated by the determination of the pre-/post-dialysis AGE differences, was comparable across all groups.
  
  
  CONCLUSIONS
  These findings suggest that factors other than removal are responsible for the lower pre-dialysis AGE levels found in patients on convective dialysis as well as on HD with UDF. A role of water quality is assumed. This is corroborated by the finding that the high molecular weight AGE-fraction is preferentially lowered in comparison with patients on HD with SDF, as analysed by gel filtration chromatography. These findings could be best explained by a less severe oxidative stress (i.e. resulting in decreased AGE generation) with HF and HDF, as well as with ultrapure HD.
authors.affiliation: Physiologische Chemie l, Biozentrum, Am Hubland, Würzburg, Germany.
authors.forename: Andrea
authors.initials: A
authors.lastname: Gerdemann
authors.forename: Zoltan
authors.initials: Z
authors.lastname: Wagner
authors.forename: Andreas
authors.initials: A
authors.lastname: Solf
authors.forename: Udo
authors.initials: U
authors.lastname: Bahner
authors.forename: August
authors.initials: A
authors.lastname: Heidland
authors.forename: Jörg
authors.initials: J
authors.lastname: Vienken
authors.forename: Reinhard
authors.initials: R
authors.lastname: Schinzel
mesh_terms: D000368:Aged; D003430:Cross-Sectional Studies; D003928:Diabetic Nephropathies / Q000097:blood / Q000628:therapy; D017127:Glycation End Products, Advanced / Q000097:blood*; D017583:Hemodiafiltration; D006440:Hemofiltration; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008875:Middle Aged; D006435:Renal Dialysis; D013050:Spectrometry, Fluorescence
chemical_list: D017127:Glycation End Products, Advanced